Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$370.04M$370.04M−13.9% vs Q3 2024 Net Income-$179.95M-$179.95MN/M vs Q3 2024 EPS Diluted-$0.50-$0.50N/M vs Q3 2024 Gross Profit$219,268,000−35.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Operating Cash Flowderived-$14,585,000N/M Free Cash Flowderived-$37,519,000N/M Margins · derivedGross margin59.3%−19.4 pt vs Q3 2024
Operating margin-27.9%−33.1 pt vs Q3 2024
Net margin-48.6%−56.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end